Statin use and risk of Parkinson's disease: A meta-analysis of observational studies

Journal of Neurology

Volumn 260, Issue 1, 2013, Pages 158-165

  Undela, Krishna ^a   Gudala, Kapil ^a   Malla, Swathi ^a   Bansal, Dipika ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Meta analysis; Parkinson's disease; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; DRUG USE; HUMAN; META ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS;

CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; OBSERVATION; PARKINSON DISEASE; PUBMED; RISK FACTORS;

EID: 84872285683     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6606-3     Document Type: Article

References (35)

1. Lang AE, Lozano AM (1998) Parkinson's disease. First of two parts. N Engl J Med 339:1044-1053
2. Schapira AH (2006) Etiology of Parkinson's disease. Neurology 66:S10-S23
3. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 26:S1-S58
4. Lamb E (2009) Top 200 drugs of 2008. http://www.pharmacytimes.com/issue/ pharmacy/2009/2009-05/RxFocusTop200Drugs-0509. Accessed 2 May 2012
5. Becker C, Meier CR (2009) Statins and the risk of Parkinson disease: an update on the controversy. Expert Opin Drug Saf 8:261-271
6. Wood WG, Eckert GP, Igbavboa U, Muller WE (2010) Statins and neuroprotection: a prescription to move the field forward. Ann NY Acad Sci 1199:69-76
7. Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA (2011) Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 230:27-34
8. Selley ML (2005) Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 1037:1-6
9. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C (2007) Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord 22:377-381
10. de Lau LM, Stricker BH, Breteler MM (2007) Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease. Mov Disord 22:1985-1987
11. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 5:20
12. Becker C, Jick SS, Meier CR (2008) Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf 31:399-407
13. Samii A, Carleton BC, Etminan M (2008) Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci 15:1272-1273
14. Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2008) Statin use and the risk of Parkinson disease. Neurology 70:1418-1422
15. Ritz B, Manthripragada AD, Qian L, Schernhammer E, Wermuth L, Olsen J, Friis S (2010) Statin use and Parkinson's disease in Denmark. Mov Disord 25:1210-1216
16. Gao X, Simon KC, Schwarzschild MA, Ascherio A (2012) Prospective study of statin use and risk of Parkinson disease. Arch Neurol 69:380-384
17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
18. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
19. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
20. Simon KC, Chen H, Schwarzschild M, Ascherio A (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69:1688-1695
21. Ottawa Hospital Research Institute (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed 2 May 2012
22. Zhang J, Yu KF (1998) What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280:1690-1691
23. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
24. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
26. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326:219
27. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012
28. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150:963-976
29. Greenamyre JT, Hastings TG (2004) Biomedicine. Parkinson's - divergent causes, convergent mechanisms. Science 304:1120-1122
30. Devaraj S, Chan E, Jialal I (2006) Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91:4489-4496
31. Resch U, Tatzber F, Budinsky A, Sinzinger H (2006) Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 61:262-274
32. Obata T, Yamanaka Y (2000) Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum. Brain Res 860:166-169
33. Murtola TJ, Tammela TL, Mllttlnen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A (2010) Prostate cancer and PSA among statin users in the Finnish Prostate Cancer Screening Trial. Int J Cancer 127:1650-1659
34. Schachter M (2004) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117-125
35. Mason RP, Walter MF, Day CA, Jacob RF (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96:11-23